PHARMASPIRE - Volume 15, Issue 01,2023 , Jan-March

Pages: 28-32
Print Article   Download XML  Download PDF

An outbreak of Marburg virus disease: World Health Organization

Author: Arvind Kumar, Ruby Gangwar, Abrar Ahmad Zargar, Hardik Kumar, Ranjeet Kumar, Amit Sharma

Category: Pharmacy Practice

Abstract:

In this review, we discussed in brief about the recent emergency update released by the World Health Organization (WHO) (July 22, 2022) on Marburg virus disease (MVD). This virus was first identified in some African countries in 1976 as hemorrhagic fever. This was noticed that year during a series of
Marburg virus (MARV) infections in German cities as well as in the Yugoslav capital of Belgrade. The epidemic was linked to research involving African apes transported from Uganda. To complete this review, we used previously published studies related to this disease and a regular visit to the WHO’s official website to know the current status of MVD. Information was collected from Google scholar, PubMed, Research gate, and national library of medicine from September 2022 to December 2022. The main objective of this study is to provide current information on MVD to researchers, practicians, health-care professionals, and academicians due to awareness. If people know about that disease, only then can they handle and prevent
it themselves. For this, we include the pathogenesis of the disease, epidemiology status, symptoms of the disease, how to diagnose according to the WHO guidelines, possible treatments according to the WHO, and a brief comparison of COVID-19 and MARV. This is a needful study for future perspective because if no one takes it seriously, then maybe in the future, it will become a severe pandemic like COVID-19.

Keywords: COVID-19, Epidemiology, Marburg virus disease, Marburg virus, Pathogenesis, World Health Organization

DOI: 10.56933/Pharmaspire.2023.15105

DOI URL: https://doi.org/10.56933/Pharmaspire.2023.15105

References:

1. Siegert R, Shu HL, Slenczka W, Peters D, Müller G. On the etiology of an unknown human infection originating from monkeys. Dtsch Med Wochenschr 1967;92:2341-3.
2. Gross L. A broken trust: Lessons from the vaccine-autism wars: Researchers long ago rejected the theory that vaccines cause autism, yet many parents don’t believe them. Can scientists bridge the gap between evidence and doubt? PLoS Biol 2009;7:e1000114 [Last accessed on 2023 Jan 02].
3. Feldmann H, Will C, Schikore M, Slenczka W, Klenk HD. Glycosylation and oligomerization of the spike protein of Marburg virus. Virology 1991;182:353-6.
4. Pöhlmann S, Simmons S, editors. Viral Entry into Host Cells. Vol. 618. New York: Springer; 2013.
5. King LB, West BR, Schendel SL, Saphire EO. The structural basis for filovirus neutralization by monoclonal antibodies. Curr Opin Immunol 2018;53:196-202.
6. Slenczka W, Klenk HD. Forty years of Marburg virus. J Infect Dis 2007;196 Suppl 2:S131-5.
7. Available from: https://www.who.int/news-room/factsheets/ detail/marburg-virus-disease [Last accessed on 2023 Jan 08].
8. Available from: https://www.bing.com/ search?q=what+is+marburg+vierse&cvid=b58cd4ceddb c4a2cb69c623164bfd3ce&aqs=edge [Last accessed on 2023 Jan 09].
9. Abir MH, Rahman T, Das A, Etu SN, Nafiz IH, Rakib A, et al. Pathogenicity and virulence of Marburg virus. Virulence 2022;13:609-33.
10. Available from: https://www.globalcitizen.org/en/ content/marburg-virus-ghana-west-africa [Last accessed on 2023 Jan 10].
11. Schuh AJ, Amman BR, Jones ME, Sealy TK, Uebelhoer LS, Spengler JR, et al. Modelling filovirus maintenance in nature by experimental transmission of Marburg virus between Egyptian Rousette bats. Nat Commun 2017;8:14446.
12. Amman BR, Schuh AJ, Albariño CG, Towner JS. Marburg virus persistence on fruit as a plausible route of bat to primate filovirus transmission. Viruses 2021;13:2394.
13. Kortepeter MG, Dierberg K, Shenoy ES, Cieslak TJ. Medical countermeasures working group of the National Ebola Training and Education Center’s (NETEC) Special Pathogens Research Network (SPRN). Marburg virus disease: A summary for clinicians. Int J Infect Dis 2020;99:233-42.
14. Bausch DG, Borchert M, Grein T, Roth C, Swanepoel R, Libande ML, et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 2003;9:1531-7.
15. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis 2011;204 Suppl 3:S810-6.
16. Miraglia CM. Marburgviruses: An update. Lab Med 2019;50:16-28.
17. Shifflett K, Marzi A. Marburg virus pathogenesis - differences and similarities in humans and animal models. Virol J 2019;16:165.
18. Stille W, Böhle E. Clinical Course and Prognosis of Marburg Virus (“Green-Monkey”) Disease. Marburg Virus Disease. Berlin, Heidelberg: Springer; 1971. p. 10-8.
19. Martini GA. Marburg virus disease. Postgrad Med J 1973;49:542-6.
20. Stonier SW, Herbert AS, Kuehne AI, Sobarzo A, Habibulin P, Dahan CV, et al. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J Exp Med 2017;214:2563-72.
21. Aborode AT, Wireko AA, Bel-Nono KN, Quarshie LS, Allison M, Bello MA. Marburg virus amidst COVID-19 pandemic in Guinea: Fighting within the looming cases. Int J Health Plann Manage 2022;37:553-5.
22. Available from: https://reliefweb.int/report/guinea/westafricas- first-ever-case-marburg-virus-disease-confirmedguinea [Last accessed on 2023 Jan 25].
23. Mohapatra RK, Sarangi AK, Kandi V, Chakraborty S, Chandran D, Alagawany M, et al. Recent re-emergence of Marburg virus disease in an African country Ghana after Guinea amid the ongoing COVID-19 pandemic: Another global threat? Current knowledge and strategies to tackle this highly deadly disease having feasible pandemic potential. Int J Surg 2022;106:106863.
24. Geisbert TW, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis 2015;212 Suppl 2:S91-7.
25. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol 2020;215:108427.
26. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. The coronavirus spike protein is a Class I virus fusion protein: Structural and functional characterization of the fusion core complex. J Virol 2003;77:8801-11.